Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

ASTRAZENECA PHARMA INDIA LTD.

NSE : ASTRAZENBSE : 506820ISIN CODE : INE203A01020Industry : Pharmaceuticals & DrugsHouse : Astrazeneca Pharma India - MNC

BSE7591.45117.45 (+1.57 %)

PREV CLOSE ( ) 7474.00

OPEN PRICE ( ) 7528.95

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 1359

TODAY'S LOW / HIGH ( )7519.20 7706.65

52 WK LOW / HIGH ( )4050.15 8139.85

NSE7625.60157.45 (+2.11 %)

PREV CLOSE( ) 7468.15

OPEN PRICE ( ) 7505.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 7625.60 (13)

VOLUME 36549

TODAY'S LOW / HIGH( ) 7505.00 7710.00

52 WK LOW / HIGH ( )4785 8139

Select year

(Rs.in Million)

Particulars

Mar 2024

Mar 2023

Mar 2022

Mar 2021

Mar 2020

Profit Before Tax

2195.40

1341.00

830.40

1270.90

1139.70

Adjustment

-70.70

-48.00

96.60

142.00

97.50

Changes In working Capital

-1281.70

-301.90

328.90

-39.50

-26.60

Cash Flow after changes in Working Capital

843.00

991.10

1255.90

1373.40

1210.60

Cash Flow from Operating Activities

278.70

582.90

1008.00

1047.80

874.20

Cash Flow from Investing Activities

217.40

181.10

47.40

1730.30

-1708.00

Cash Flow from Financing Activities

-443.80

-244.80

-94.60

-89.70

-63.60

Net Cash Inflow / Outflow

52.30

519.20

960.80

2688.40

-897.40

Opening Cash & Cash Equivalents

5003.40

4484.20

3523.40

835.00

1732.40

Cash & Cash Equivalent on Amalgamation / Take over / Merger

Cash & Cash Equivalent of Subsidiaries under liquidations

Translation adjustment on reserves / op cash balalces frgn subsidiaries

Effect of Foreign Exchange Fluctuations

Closing Cash & Cash Equivalent

5055.70

5003.40

4484.20

3523.40

835.00